SciClone Pharmaceuticals Inc (SCLN)

10.95
0.05 0.46
NASDAQ : Health Care
Prev Close 10.90
Open 10.95
Day Low/High 10.90 / 10.95
52 Wk Low/High 6.47 / 15.03
Volume 311.27K
Avg Volume 596.60K
Exchange NASDAQ
Shares Outstanding 51.79M
Market Cap 567.10M
EPS 0.60
P/E Ratio 15.42
Div & Yield N.A. (N.A)

Latest News

INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors Of An Investigation Concerning Whether The Sale Of SciClone Pharmaceuticals Inc. To A Consortium Is Fair To Shareholders

The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased SciClone Pharmaceuticals Inc.

SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of SciClone Pharmaceuticals, Inc. And Encourages Investors To Contact The Firm For Additional Information

The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of SciClone...

Drug Price Inflation and a Patent Cliff Could Trigger a Wave of Deals in Generic Drugs Space

Drug Price Inflation and a Patent Cliff Could Trigger a Wave of Deals in Generic Drugs Space

Generic drugmakers are likely to limit themselves to acquisitions of small- and mid-sized companies in the immediate future because of over-leveraging and turmoil in the executive ranks..

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces An Investigation Concerning Whether The Sale Of SciClone Pharmaceuticals Inc. To A Consortium Is Fair To Shareholders - SCLN

The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased SciClone Pharmaceuticals Inc.

Bullish Two Hundred Day Moving Average Cross - SCLN

In trading on Friday, shares of SciClone Pharmaceuticals, Inc. crossed above their 200 day moving average of $9.98, changing hands as high as $10.04 per share.

Merck Up on Approval, Teva Sinks on Earnings and Asset Sales: Biotech Movers

Merck Up on Approval, Teva Sinks on Earnings and Asset Sales: Biotech Movers

The approval marks the first time that an immunotherapy has been combined with another drug to kill cancer cells more effectively.

Short Interest In SciClone Pharmaceuticals Drops 17.6%

Short Interest In SciClone Pharmaceuticals Drops 17.6%

The most recent short interest data has been released for the 10/31/2016 settlement date, which shows a 462,133 share decrease in total short interest for SciClone Pharmaceuticals, Inc. , to 2,167,158, a decrease of 17.58% since 10/14/2016.

Commit To Buy SciClone Pharmaceuticals At $7.50, Earn 10.4% Annualized Using Options

Commit To Buy SciClone Pharmaceuticals At $7.50, Earn 10.4% Annualized Using Options

Investors considering a purchase of SciClone Pharmaceuticals, Inc. shares, but tentative about paying the going market price of $9.03/share, might benefit from considering selling puts among the alternative strategies at their disposal.

SciClone Pharmaceuticals Becomes Oversold

SciClone Pharmaceuticals Becomes Oversold

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Soligenix And SciClone Establish Regional Licensing Agreement For SGX942, A Novel Product Candidate For Oral Mucositis

Soligenix And SciClone Establish Regional Licensing Agreement For SGX942, A Novel Product Candidate For Oral Mucositis

Agreement Includes Greater China and Other East Asia Markets

SciClone Pharmaceuticals Becomes Oversold (SCLN)

SciClone Pharmaceuticals Becomes Oversold (SCLN)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

SciClone Pharmaceuticals Stock Sees Short Interest Drop 21.2%

SciClone Pharmaceuticals Stock Sees Short Interest Drop 21.2%

The most recent short interest data has been released for the 07/29/2016 settlement date, which shows a 528,413 share decrease in total short interest for SciClone Pharmaceuticals, Inc. , to 1,960,649, a decrease of 21.23% since 07/15/2016.

SciClone Pharmaceuticals is Now Oversold (SCLN)

SciClone Pharmaceuticals is Now Oversold (SCLN)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Interesting SCLN Put And Call Options For August 19th

Interesting SCLN Put And Call Options For August 19th

Investors in SciClone Pharmaceuticals, Inc. saw new options begin trading this week, for the August 19th expiration.

Today's Weak On High Volume Stock: SciClone Pharmaceuticals (SCLN)

Today's Weak On High Volume Stock: SciClone Pharmaceuticals (SCLN)

Trade-Ideas LLC identified SciClone Pharmaceuticals (SCLN) as a weak on high relative volume candidate

SciClone Pharmaceuticals (SCLN): Today's Weak On High Volume Stock

SciClone Pharmaceuticals (SCLN): Today's Weak On High Volume Stock

Trade-Ideas LLC identified SciClone Pharmaceuticals (SCLN) as a weak on high relative volume candidate

Jim Cramer's 'Mad Money' Recap: Here's This Week's Game Plan

Jim Cramer's 'Mad Money' Recap: Here's This Week's Game Plan

Oil controls the market, and Cramer is watching stocks to see which you should be buying.

'Mad Money' Lightning Round: Con Ed, Regeneron Are My Picks

'Mad Money' Lightning Round: Con Ed, Regeneron Are My Picks

Cramer is no fan of J.C. Penney and says NCR is up too much.

Interesting SCLN Put And Call Options For May 20th

Interesting SCLN Put And Call Options For May 20th

Investors in SciClone Pharmaceuticals, Inc. saw new options become available this week, for the May 20th expiration.

Commit To Purchase SciClone Pharmaceuticals At $7.50, Earn 12.2% Annualized Using Options

Commit To Purchase SciClone Pharmaceuticals At $7.50, Earn 12.2% Annualized Using Options

Investors considering a purchase of SciClone Pharmaceuticals, Inc. shares, but tentative about paying the going market price of $9.74/share, might benefit from considering selling puts among the alternative strategies at their disposal.

Bullish Two Hundred Day Moving Average Cross - SCLN

Bullish Two Hundred Day Moving Average Cross - SCLN

In trading on Friday, shares of SciClone Pharmaceuticals, Inc. crossed above their 200 day moving average of $8.58, changing hands as high as $8.93 per share.

SciClone Pharmaceuticals Becomes Oversold (SCLN)

SciClone Pharmaceuticals Becomes Oversold (SCLN)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Insider Trading Alert - MW, SCLN And ATHN Traded By Insiders

Insider Trading Alert - MW, SCLN And ATHN Traded By Insiders

Stocks with insider trader activity include MW, SCLN and ATHN

Commit To Purchase SciClone Pharmaceuticals At $10, Earn 26.9% Annualized Using Options

Commit To Purchase SciClone Pharmaceuticals At $10, Earn 26.9% Annualized Using Options

Investors considering a purchase of SciClone Pharmaceuticals, Inc. shares, but tentative about paying the going market price of $10.01/share, might benefit from considering selling puts among the alternative strategies at their disposal.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ADT, AIN, BDBD, CBS.A, CRAY, EGT, FPRX, GERN, HMPR, ISIL, SCLN Downgrades: ASM, BRS, SRDX Initiations: DPLO, W Read on to get TheStreet Quant Ratings' detailed report: